Edesa Biotech (EDSA) Gains from Investment Securities (2021)
Edesa Biotech (EDSA) posted Gains from Investment Securities of -$1.0 for Q3 2021.
Edesa Biotech (EDSA) Gains from Investment Securities (2021) Analysis & Trends
Edesa Biotech has reported Gains from Investment Securities for 1 years, with the latest figure at -$1.0 in Q3 2021.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$1.0 in Q3 2021, while the trailing twelve-month figure through Jun 2023 was -$1.0 (changed N/A YoY) and the FY2022 annual result came in at $408059.0, changed 0.25% from the prior year.
- Gains from Investment Securities steadied at -$1.0 in Q3 2021 per EDSA's latest filing.
- Over five years, Gains from Investment Securities peaked at -$1.0 in Q3 2021 and troughed at -$1.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -1.00 |
| Sep 30, 2021 | -1.00 |